Hepatitis E virus (HEV) is highly endemic in developing
|
|
- Alan Melton
- 6 years ago
- Views:
Transcription
1 Annals of Internal Medicine Article Brief Communication: Case Reports of Ribavirin Treatment for Chronic Hepatitis E Vincent Mallet, MD, PhD; Elisabeth Nicand, MD; Philippe Sultanik, MD; Catherine Chakvetadze, MD; Sophie Tessé, PhD; Eric Thervet, MD, PhD; Luc Mouthon, MD, PhD; Philippe Sogni, MD, PhD; and Stanislas Pol, MD, PhD Background: There is currently no accepted treatment of chronic hepatitis E virus (HEV) infection. Objective: To report 2 patients in whom ribavirin therapy seemed to alter the natural history of chronic HEV infection. Design: Case reports. Setting: Hepatology unit of a tertiary care center in France. Patients: A kidney and pancreas transplant recipient and a patient with idiopathic CD4 T lymphocytopenia, both with biopsy-proven chronic HEV infection. Intervention: Patients received oral ribavirin, 12 mg/kg of body weight daily for 12 weeks. Results: Both patients had normalized liver function test results after 2 weeks of treatment and cleared HEV after 4 weeks of treatment. Hepatitis E virus RNA remained undetectable in the serum and stools throughout follow-up (3 months and 2 months for the first and second patient, respectively). Side effects were considered mild. Limitation: Given the relatively short follow-up, the achievement of HEV eradication could not be claimed. Conclusion: Ribavirin is a potentially effective treatment of HEV infection and should be evaluated in patients with chronic HEV infection. Primary Funding Source: None. Measurements: Liver function tests, detection of HEV RNA (viremia and stool shedding) by reverse transcriptase polymerase chain reaction, and anti-hev IgM and IgG antibodies. Ann Intern Med. 2010;153: For author affiliations, see end of text. This article was published at on 15 June Hepatitis E virus (HEV) is highly endemic in developing countries and is an emerging autochthonous (locally acquired) disease in industrialized countries in which a preferential zoonotic method of transmission is reported (1). Acute HEV infection has a high mortality rate in older persons, pregnant women, and patients with underlying chronic liver disease (25). Acute HEV infection can also evolve into chronic infection in immunocompromised patients (6, 7). The reported rate of chronicity after HEV infection is approximately 60% in solid-organ transplant recipients with persistent viral shedding observed in blood, stool, and liver biopsy samples for up to 7 years (810). The diagnosis of HEV infection is based on the detection of HEV RNA in blood, stool, or liver biopsy samples and specific anti-hev IgM and IgG antibodies. In some patients, including nonimmunocompromised patients, the course, maturation, and duration of anti-hev IgG and IgM antibodies may be altered, and silent serologic acute or chronic hepatitis E cases have been reported (7, 9). Chronic HEV infection can lead to cirrhosis and endstage liver disease; in transplant recipients, it can lead to loss of liver graft (8, 11, 12). The prevalence of chronic HEV infection in transplant recipients is estimated from 0.4% in low endemic areas to 1.9% in areas with a higher prevalence (8, 12, 13). The incidence of chronic HEV infection in immunocompromised patients is difficult to estimate because of a lack of systematic HEV screening in this population. Nevertheless, the French National Reference Laboratory has reported an increasing number of cases of chronic HEV infection in immunocompromised patients in France (14). Currently, no accepted treatment of chronic HEV infection exists, although cases of HEV clearance have been reported in transplant recipients once their immunosuppressive medication was tapered or when interferon- was administered. Both approaches, however, introduce the risk for graft rejection (10, 15, 16). Regarding management of acute HEV infection, clinical intervention is limited to supportive care. Ribavirin [1-( -D-ribofuranosyl)-1,2,4-triazole-3-carboxamide) is a guanosine analogue that has broad-spectrum activity against DNA and RNA viruses, including activity against Orthomyxoviridae, Herpesviridae, respiratory syncytial viruses, Flaviviridae, and agents of many viral hemorrhagic fevers (17). Ribavirin (combined with interferon) has been used since the early 1990s to treat chronic hepatitis C infection and has been used as monotherapy in transplant recipients with chronic hepatitis C virus infection (1821). We report the efficacy of ribavirin in 2 immunocompromised patients with chronic HEV infection. See also: Print Editors Notes Web-Only Conversion of graphics into slides 2010 American College of Physicians 85
2 Article Ribavirin for Chronic Hepatitis E Context Chronic hepatitis E virus (HEV) infection is an emerging infectious disease in immunocompromised patients. Therapy has been limited to supportive measures. Contribution In 2 patients with chronic HEV infection who received treatment with ribavirin, liver enzyme levels normalized and the virus was no longer detected in blood and stool. These results persisted after treatment was stopped. Caution Longer follow-up of these 2 patients is needed. Controlled trials of ribavirin treatment in patients with chronic HEV infection are needed to determine efficacy. In addition, ribavirin is contraindicated in pregnancy (U.S. Food and Drug Administration category X drug). Implication Antiviral therapy of chronic HEV infection may be possible. The Editors CASE REPORTS Case 1 The first patient was a diabetic white man aged 40 years who, after 2 years of hemodialysis, received a first simultaneous kidney and pancreas transplant from a deceased donor in November The immunosuppressive regimen included an initial 10-day course of antithymoglobulins; corticosteroids, 500 mg/d at day 0 followed by rapid tapering to reach 10 mg/d; tacrolimus dosed to achieve a targeted trough concentration between 10 and 15 ng/ml; and mycophenolate mofetil, 1000 mg/d, adapted to clinical outcome. The patient did not have any signs of acute rejection and was free of insulin when discharged, with a serum creatinine level of 90 mol/l (1 mg/dl). In January 2006, the patient presented to our unit for unexplained hepatitis lasting longer than the previous 38 months. Physical examination was normal. Serum alanine aminotransferase (ALT) level was 1.6 times the upper limit of the normal range. Aspartate aminotransferase (AST), -glutamyltransferase (GGT), and alkaline phosphatase levels were normal. Total bilirubin level was 19 mol/l (1.1 mg/dl), with predominance of unconjugated bilirubin. Serum creatinine level was 144 mol/l (1.6 mg/dl). Prothrombin time was normal. The patient tested positive for anti hepatitis C virus antibodies and negative for anti hepatitis B virus IgG core antibodies. Genome amplifications of hepatitis B virus, hepatitis C virus, cytomegalovirus, herpes simplex virus, and EpsteinBarr virus were all negative. Ferritin and transferrin saturation blood levels were normal; antiliver and antinuclear antibodies were negative; and serum 1 -antitrypsin, copper, and ceruloplasmin levels were normal which ruled out hemochromatosis, autoimmune hepatitis, and 1 -antitrypsin deficiency and Wilson disease, respectively. Liver ultrasonography findings were normal. Hepatitis C virus genome remained undetectable over time (limit of detection, 12 IU/mL). Hepatitis E virus infection was diagnosed in September 2008 on the basis of amplification of HEV RNA (genotype 3f; GenBank accession number GU936617) and detection of anti-hev IgG and anti-hev IgM antibodies (EIAgen HEV IgG and EIAgen HEV IgM, Adaltis, Bologna, Italy) in the serum (Figure 1). In our study, HEV RNA was amplified with primers targeting the HEV open reading frame 2 region. Two reverse transcriptase polymerase chain reaction (RT-PCR) methods were used: real-time polymerase chain reaction that was sensitive for all HEV genotypes and conventional RT-PCR, followed by sequence analysis of the 330-nucleotide open reading frame 2 product. The detection limit of RT-PCR was 100 copies of equivalent genome per milliliter of serum by using serial 10-fold dilutions of plasmid DNA (pgem-hev) as a standard curve (22). Amplification of glyceraldehyde 3-phosphate dehydrogenase was used as an internal control to rule out RT-PCR inhibitors. An IgG avidity index at 97% suggested past contact with the virus. Serum and plasma samples collected at the time of the transplantation in 1998 and stored until 2008 at 80 C were screened retrospectively, and possible exposure to the virus was dated to 2003 based on the detection of both anti-hev IgM and IgG antibodies; however, HEV RNA could not be amplified in both techniques. In 2007, HEV RNA was detected, showing a 99.5% identity with the genome sequence amplified in A 30-mm liver biopsy (spanning 10 portal tracts) was done in April 2009 and showed evidence of chronic hepatitis with moderate activity and extensive fibrosis (METAVIR activity [A] and fibrosis [F] scores of A2 and F3). The liver biopsy showed no steatosis, steatohepatitis, or vascular abnormality. The CD4 T-lymphocyte count was cells/l at that time. The CD8 T-lymphocyte count was cells/l. The patient had never traveled to endemic areas but did report frequent consumption of undercooked pork, suggesting an autochthonous zoonotic transmission method of HEV. In September 2009 (82 months after the presumed date of initial infection), ribavirin treatment, 400 mg twice daily (total daily dose, 12.3 mg/kg of body weight), was initiated with the informed consent of the patient. The immunosuppressive regimen was not modified. Two weeks later, ALT, AST, and GGT levels returned to withinnormal limits. Four weeks after the initiation of ribavirin treatment, HEV RNA was undetectable (under the limit of detection of the assay) in the serum, and HEV IgM antibodies were negative. No fecal specimen was available for HEV RNA detection at that time. All of these findings were confirmed at weeks 6, 8, 10, and 12 of treatment. Ribavirin dose was progressively decreased to 200 mg/d because of mild anemia (nadir hemoglobin level, 92 g/l), and treatment was stopped after 12 weeks. Three months July 2010 Annals of Internal Medicine Volume 153 Number 2
3 Ribavirin for Chronic Hepatitis E Article Figure 1. Laboratory data over 2 years for a kidney and pancreas transplant recipient with chronic HEV infection treated with oral ribavirin for 12 wk. 6 Tacrolimus, 10 mg/d 5 Mycophenolate mofetil, 500 mg/d ALT (x ULN) Prednisone, 5 mg/d Ribavirin, 12 mg/kg/d Jan Apr-08 2-Aug Nov Feb May-09 6-Sept Dec Mar-10 HEV IgG (ELISA) HEV IgM (ELISA) HEV RT-PCR assay (serum) HEV RT-PCR assay (stool) The graph plots the number of times the ALT level was above the ULN, by date. Genome amplifications of hepatitis B virus and hepatitis C virus were both negative. Other causes of chronic liver disease, including hemochromatosis, autoimmune hepatitis, 1 -antitrypsin deficiency, and Wilson disease, were also ruled out. For the serologic and RT-PCR tests, a plus symbol indicates a positive result and a minus symbol indicates a negative result. ALT alanine aminotransferase; ELISA enzyme-linked immunosorbent assay; HEV hepatitis E virus; RT-PCR reverse transcriptase polymerase chain reaction; ULN upper limit of normal. after cessation of treatment, liver function test results remained normal and HEV RNA was undetected in serum and stool. Case 2 The second patient was a white woman aged 57 years with idiopathic CD4 T lymphocytopenia and a primary deficiency in IgG-1, -2, and -4 subclasses. Her medical history included recurrent upper respiratory tract infections since childhood, with secondary bronchiectasia and moderate chronic respiratory insufficiency, and chronic cutaneous and genital human papillomavirus infection that evolved to chronic epidermodysplasia verruciformis (since age 7 years), Bowen disease (age 47 years), spinocellular cancer (age 47 years), and intraepithelial neoplasia of the vulva (age 48 years). She also reported primary cancer of the breast (age 37 years), appendicular abscess (age 52 years), and several episodes of urolithiasis. She was first seen in our unit in July 2009 for abnormal liver function test results and a 10-kg weight loss over the previous 6 months. Apart from the dermatologic lesions, the physical examination was normal. Levels of ALT, AST, GGT, and alkaline phosphatase were 8, 5, 7.5, and 1 times the upper limit of the normal range, respectively. Total bilirubin level was 14 mol/l (0.8 mg/dl). The CD4 T-lymphocyte count was cells/l. The CD8 T-lymphocyte count was cells/l. The CD19 B-lymphocyte count was cells/l. The serum creatinine level was 63 mol/l (0.7 mg/dl). Prothrombin time index was 97%. The patient tested negative for antihepatitis A virus IgM antibodies, antihepatitis C virus antibodies, anti hepatitis B virus IgG core antibodies, and antihev antibodies (HEV IgG enzymelinked immunosorbent assay, Abbott Laboratories, Park, Illinois). Genome amplifications of hepatitis B virus, hepatitis C virus, cytomegalovirus, herpes simplex virus, and EpsteinBarr virus were negative. Ferritin blood level was normal; antiliver and antinuclear antibodies were negative; and serum 1 -antitrypsin, copper, and ceruloplasmin levels were normal. Liver ultrasonography findings were normal. In December 2009, a 9-mm liver biopsy (spanning 10 portal tracts) showed evidence of chronic hepatitis, with moderate activity and mild fibrosis (METAVIR scores of A2 and F1). At that time, HEV RNA was amplified (genotype 3c; GenBank accession number HM066937) from both serum and stool samples (Figure 2), and a low anti- HEV IgM reactivity (EIAgen HEV IgM) was detected in the absence of a detectable anti-hev IgG antibody (EIAgen HEV IgG). Two previous serum samples collected in April and July 2009 (stored at 80 C) were positive for HEV RNA and anti-hev IgM antibody, confirming chronic HEV infection. The patient reported having traveled to the south of France in November 2008 where she consumed pig liver sausage, suggesting autochthonous zoonotic transmission. Two weeks later (12 months after the presumed date of infection), ribavirin treatment, 600 mg/d divided into 2 doses (total daily dose, 12 mg/kg), was initiated with the informed consent of the patient. Two weeks later, ALT and AST levels returned to normal 20 July 2010 Annals of Internal Medicine Volume 153 Number 2 87
4 Article Ribavirin for Chronic Hepatitis E Figure 2. Laboratory data over 1 year for a patient with idiopathic CD4 T lymphocytopenia and chronic HEV infection treated with oral ribavirin for 3 wk. ALT (x ULN) Feb-09 Ribavirin, 12 mg/kg/d 9-Apr May Jul-09 6-Sept Oct Dec Feb Mar May-10 HEV IgG (ELISA) HEV IgM (ELISA) HEV RT-PCR assay (serum) ±± HEV RT-PCR assay (stool) The graph plots the number of times the ALT level was above the ULN, by date. Genome amplifications of hepatitis B virus and hepatitis C virus were both negative. Other causes of chronic liver disease, including hemochromatosis, autoimmune hepatitis, 1 -antitrypsin deficiency, and Wilson disease, were also ruled out. For the serologic and RT-PCR tests, a plus symbol indicates a positive result, a minus symbol indicates a negative result, and a plus/minus symbol indicates a positive test result at the limit of detection of the RT-PCR assay. ALT alanine aminotransferase; ELISA enzymelinked immunosorbent assay; HEV hepatitis E virus; RT-PCR reverse transcriptase polymerase chain reaction; ULN upper limit of normal. limits. After 4 weeks of treatment, HEV RNA was undetectable in the serum and stools. Ribavirin treatment was stopped after 12 weeks. Two months after the end of treatment, liver function test results remained normal and HEV RNA was not amplified from either serum or stool. DISCUSSION Because ribavirin monotherapy has broad-spectrum antiviral activity against RNA viruses and is rather well tolerated, we investigated its efficacy in 2 immunocompromised patients with biopsy-proven chronic HEV infection lasting for 82 months and more than 12 months, respectively. We observed a normalization of liver function test results after 2 weeks of treatment, and clearance of HEV RNA was attained by week 4 in both patients. To our knowledge, this is the first description of the efficacy of a nucleoside analogue for the management of patients with hepatitis E. Given the absence of available treatment, our results suggest that ribavirin should be tested in larger patient cohorts as a strategy for improving the natural course and management of patients with severe forms of HEV. One limitation of this case report is the lack of long-term follow-up. Clearly, viral eradication is the desired outcome, and evaluation of different dosing and treatment schedules may be required to achieve this goal. Nonetheless, our findings represent the first milestone toward an effective treatment of chronic HEV infection without increasing the risk for graft rejection in transplant recipients or increasing the level of primary or acquired immune deficiency. Ribavirin is phosphorylated in human cells to ribavirin monophosphate, which is then converted to ribavirin triphosphate. Ribavirin monophosphate inhibits inosine monophosphate dehydrogenase and consequently reduces cellular guanosine triphosphate levels, which can interfere with viral (and host) nucleic acid synthesis. Ribavirin triphosphate directly interacts with the viral polymerase. We observed the same kinetics of normalization of liver function test results and of HEV clearance in both patients 1 of them having received mycophenolate mofetil, which is another inosine monophosphate dehydrogenase inhibitor. This observation could favor a direct inhibition of HEV polymerase by ribavirin rather than an antiviral activity on the basis of guanosine depletion. This hypothesis should be evaluated in vitro (23). The primary toxicity of ribavirin is anemia. When ribavirin dose is based on weight (800 to 1400 mg/d) and is used in combination with interferon, the reported rate of anemia (hemoglobin level 100 g/l) is 19.3%. Anemia induced by ribavirin is usually mild and may be reversed July 2010 Annals of Internal Medicine Volume 153 Number 2
5 Ribavirin for Chronic Hepatitis E Article when dosing is decreased. In the management of chronic hepatitis C virus, this approach obviates the need to interrupt treatment (24). Ribavirin-associated anemia usually occurs during the first 2 weeks of treatment, and the maximum decrease in hemoglobin levels is typically observed during the first 8 weeks. Therefore, close monitoring of hemoglobin levels is mandatory. The U.S. Food and Drug Administration classifies ribavirin as a category X drug, indicating high teratogenic probability based on animal studies and defined mechanism of action. Hence, the drug is contraindicated in pregnant women. Ribavirin should not be used in pregnant patients with HEV infection because of the preliminary nature of these 2 case reports (25). In conclusion, ribavirin seems to have potent activity against HEV and should be further evaluated in chronic as well as severe forms of acute HEV infection. From Institut Cochin, Université Paris Descartes (Unité Mixte de Recherche S1016), Centre National de la Recherche Scientifique (Unité Mixte de Recherche 8104), Institut National de la Santé et de la Recherche Medicale U.1016, Centre Universitaire des Saints-Pères (Unité Mixte de Recherche 775), Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Cochin Saint-Vincent de Paul, Hôpital Necker Enfants Malades, and Hôpital d Instruction des Armées du Val-de-Grâce, Paris, France. Note: Drs. Mallet, Sogni, and Pol contributed equally to this article. Acknowledgment: The authors acknowledge the patients readiness to help others by accepting their case be the focus of this article. The authors also thank Anaïs Vallet-Pichard, MD; Hélène Fontaine, MD; Matthew Albert, MD, PhD; and Marie Françoise Avril, MD, PhD, for their help in the care of the reported patients and for their advice on the manuscript. Potential Conflicts of Interest: Disclosures can be viewed at M Reproducible Research Statement: Study protocol and statistical code: Not available. Data set: Available from Dr. Mallet ( , after establishing written agreement with the authors. Requests for Single Reprints: Vincent Mallet, MD, PhD, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Cochin Saint-Vincent de Paul, Unité d Hépatologie, 27 rue du Faubourg Saint Jacques, Paris, France; , vincent.mallet@cch.aphp.fr. Current author addresses and author contributions are available at References 1. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8: [PMID: ] 2. Mast EE, Krawczynski K. Hepatitis E: an overview. Annu Rev Med. 1996; 47: [PMID: ] 3. Dalton HR, Stableforth W, Hazeldine S, Thurairajah P, Ramnarace R, Warshow U, et al. Autochthonous hepatitis E in Southwest England: a comparison with hepatitis A. Eur J Clin Microbiol Infect Dis. 2008;27: [PMID: ] 4. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R. Locally acquired hepatitis E in chronic liver disease [Letter]. Lancet. 2007;369:1260. [PMID: ] 5. Péron JM, Bureau C, Poirson H, Mansuy JM, Alric L, Selves J, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat. 2007;14: [PMID: ] 6. Péron JM, Mansuy JM, Récher C, Bureau C, Poirson H, Alric L, et al. Prolonged hepatitis E in an immunocompromised patient [Letter]. J Gastroenterol Hepatol. 2006;21: [PMID: ] 7. Tamura A, Shimizu YK, Tanaka T, Kuroda K, Arakawa Y, Takahashi K, et al. Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res. 2007;37: [PMID: ] 8. Kamar N, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358: [PMID: ] 9. Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2008;14: [PMID: ] 10. Kamar N, Abravanel F, Selves J, Garrouste C, Esposito L, Lavayssière L, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-e virus infection after organ transplantation. Transplantation. 2010; 89: [PMID: ] 11. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection [Letter]. N Engl J Med. 2009; 361: [PMID: ] 12. Haagsma EB, Niesters HG, van den Berg AP, Riezebos-Brilman A, Porte RJ, Vennema H, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2009;15: [PMID: ] 13. Pischke S, Suneetha PV, Baechlein C, Barg-Hock H, Heim A, Kamar N, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl. 2010;16: [PMID: ] 14. French National Reference Laboratory. Annual Report 2008 [in French]. Accessed at on 21 May Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl. 2010;16: [PMID: ] 16. Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau- Desangles I, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50:e30-3. [PMID: ] 17. Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res. 2005; 107: [PMID: ] 18. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 1991;337: [PMID: ] 19. Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc. 1997;29:783. [PMID: ] 20. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis. 2003; 42: [PMID: ] 21. Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation. 2004;78: [PMID: ] 22. Enouf V, Dos Reis G, Guthmann JP, Guerin PJ, Caron M, Marechal V, et al. Validation of single real-time TaqMan PCR assay for the detection and quantitation of four major genotypes of hepatitis E virus in clinical specimens. J Med Virol. 2006;78: [PMID: ] 23. Tanaka T, Takahashi M, Kusano E, Okamoto H. Development and evaluation of an efficient cell-culture system for Hepatitis E virus. J Gen Virol. 2007;88: [PMID: ] 24. Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, et al; WIN-R Study Group. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007;46: [PMID: ] 25. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 8th ed. Philadelphia: Lippincott Williams & Wilkins; July 2010 Annals of Internal Medicine Volume 153 Number 2 89
6 Annals of Internal Medicine Current Author Addresses: Drs. Mallet, Sultanik, Chakvetadze, Sogni, and Pol: Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Cochin Saint-Vincent de Paul, Unité d Hépatologie, 27 rue du Faubourg Saint Jacques, Paris, France. Drs. Nicand and Tessé: Hôpital d Instruction des Armées du Val-de- Grâce, Centre National de Référence des hépatites à transmission entérique (hépatite E), 74 boulevard de Port-Royal, Paris, France. Dr. Thervet: Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, Unité de Transplantation rénale, 149 rue de Sèvres, Paris, France. Dr. Mouthon: Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Cochin Saint-Vincent de Paul, Service de Médecine Interne, 27 rue du Faubourg Saint Jacques, Paris, France. Author Contributions: Conception and design: V. Mallet, S. Pol. Analysis and interpretation of the data: V. Mallet, E. Nicand, S. Tessé, L. Mouthon, P. Sogni, S. Pol. Drafting of the article: V. Mallet, E. Nicand, E. Thervet, P. Sogni. Critical revision of the article for important intellectual content: V. Mallet, E. Thervet, P. Sogni, S. Pol. Final approval of the article: V. Mallet, C. Chakvetadze, E. Thervet, L. Mouthon, P. Sogni, S. Pol. Provision of study materials or patients: V. Mallet, E. Nicand, P. Sultanik, C. Chakvetadze, E. Thervet, L. Mouthon, P. Sogni. Administrative, technical, or logistic support: V. Mallet, P. Sultanik, S. Tessé, S. Pol. Collection and assembly of data: V. Mallet, C. Chakvetadze, E. Thervet July 2010 Annals of Internal Medicine Volume 153 Number 2 W-31
Hépatite E & transplantation d organes Pr Nassim KAMAR
Hépatite E & transplantation d organes Pr Nassim KAMAR Service de Néphrologie, Dialyse et Transplantation d Organes CHU Rangueil- Toulouse Genotype 3 HEV infection is an emerging disease in developing
More informationTransmission of HEV by plasmapheresis. Vincent Mallet, MD, PhD CHU Cochin, Université Paris Descartes, APHP, Inserm
Transmission of HEV by plasmapheresis Vincent Mallet, MD, PhD CHU Cochin, Université Paris Descartes, APHP, Inserm Transmission of HEV by secured plasma Transmission of HEV by plasma IA Transmission of
More informationCurrent Treatment of Acute and Chronic Hepatitis E Virus Infection: Role of Antivirals
MINI REVIEW Current Treatment 10.5005/jp-journals-10018-1216 of Acute and Chronic HEV Infection Current Treatment of Acute and Chronic Hepatitis E Virus Infection: Role of Antivirals 1 Ananta Shrestha,
More informationChronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh
Chronic Hepatitis Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh Autoimmune Hepatitis Annual incidence 1.9/100 000 in N Europe Prevalence 16.9/100 000 ~5% all liver transplants Female preponderance
More informationHepatitis E virus (HEV) is a well-known cause of
GASTROENTEROLOGY 2011;140:1481 1489 Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants NASSIM KAMAR,*,, CYRIL GARROUSTE,*,
More informationChronic Hepatitis E Resolved by Reduced Immunosuppression in Pediatric Kidney Transplant Patients
Chronic Hepatitis E Resolved by Reduced Immunosuppression in Pediatric Kidney Transplant Patients Antonia H.M. Bouts, MD, PhD a, Pytrik J. Schriemer, MD a, Hans L. Zaaijer, MD, PhD b,c At present, transient
More informationNew recommendations for immunocompromised patients
New recommendations for immunocompromised patients Hepatitis E Virus (HEV): Transmission, incidence and presentation Emerging evidence regarding HEV transmission from blood components and dietary consumption
More informationRibavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients
The new england journal of medicine original article Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients Nassim Kamar, M.D., Ph.D., Jacques Izopet, Pharm.D., Ph.D., Simona Tripon,
More informationHepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients
brief report Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients Nassim Kamar, M.D., Ph.D., Janick Selves, M.D., Jean-Michel Mansuy, M.D., Leila Ouezzani, M.D., Jean-Marie Péron, M.D.,
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationUnexplained liver enzyme elevation is frequently
Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland Alain Kenfak-Foguena, 1 Franziska Schöni-Affolter, 1 Philippe Bürgisser, Andrea Witteck, Katharine E.A. Darling,
More informationHepatitis E in South Africa. Tongai Maponga
Hepatitis E in South Africa Tongai Maponga 7th FIDSSA CONGRESS 2017 This is what usually comes to mind History of hepatitis E virus An ET-NANB hepatitis virus later named HEV was first suspected in 1980.
More informationHepatitis E Virus Infection. Disclosures
Hepatitis E Virus Infection Simona Rossi, MD Associate Chair, Division of Hepatology Einstein Medical Center Philadelphia Consultant for BMS Speaker for Gilead Disclosures I have no conflicts to report
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationChronic hepatitis E virus infection in a patient with leukemia and elevated transaminases: a case report
Gauss et al. Journal of Medical Case Reports 2012, 6:334 JOURNAL OF MEDICAL CASE REPORTS CASE REPORT Open Access Chronic hepatitis E virus infection in a patient with leukemia and elevated transaminases:
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationHepatitis E virus infection in dialysis and transplant-patients
Hepatitis E virus infection in dialysis and transplant-patients patients Pr Nassim KAMAR Department of Nephrology, Dialysis, and Organ Transplantation Toulouse University Hospital France Hepatitis E virus
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationHepatitis E in humans. Alfredo Pérez (Hospital 12 de Octubre, Madrid. Spain)
Hepatitis E in humans Alfredo Pérez (Hospital 12 de Octubre, Madrid. Spain) VIRAL HEPATITIS Those caused by different viruses with primary tropism for the liver tissue History (discovery) Hepatitis A Hepatitis
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More informationDetection of IgA-class anti-hev antibody
Detection of IgA-class anti-hev antibody Hiroaki OKAMOTO E IgA-HE IgA HEV E HEV E E E 10 E 1997 E E 1, 2 2001 E 3 HEV 4 1979 HEV 5 A B C A B C E 6, 7 E HEV E 8 11 2003 8 19 http:www.mhlw. go.jphoudou200308h0819-2.html
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationViral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH
Viral hepatitis Blood Born hepatitis Dr. MONA BADR Assistant Professor College of Medicine & KKUH Outline Introduction to hepatitis Characteristics of viral hepatitis Mode of transmission Markers of hepatitis
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationHepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
More informationAcute hepatitis A to E, diagnosis and management
Acute hepatitis A to E, diagnosis and management Thomas Berg Section of Hepatology Clinic for Gastroenterology and Rheumatology University Clinic Leipzig Acute hepatitis A to E: Topics Frequency and epidemiological
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationHepatitis E: When to think about? How to treat? Heiner Wedemeyer
Hepatitis E: When to think about? How to treat? Heiner Wedemeyer August 26 2016 Is hepatitis E really a problem? Numbers The Disease Pathogenesis Treatment Hepatitis E - Waterborne hepatitis, first described
More informationTransfusion-transmitted hepatitis E in a misleading context of autoimmunity and drug-induced toxicity
Transfusion-transmitted hepatitis E in a misleading context of autoimmunity and drug-induced toxicity Stéphanie Haïm-Boukobza 1,2,3, Marie-Pierre Ferey 1, Anne-Laure Vétillard 4, Asma Jeblaoui 1, Elisabeth
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationCurrent concepts in hepatitis E. Does it exist in Greece?
Current concepts in hepatitis E. Does it exist in Greece? Nikolaos K. Gatselis Department of Medicine and Research Lab of Internal Medicine Larissa Medical School Thessaly University Discovery of Hepatitis
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests
More informationManagement of Patients with Past or Present Hepatic Abnormalities
S21 Management of Patients with Past or Present Hepatic Abnormalities Evidence Based Medicine Official recommendations Expert opinion Course of action before tocilizumab therapy in patients with a history
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Thompson AJV; Expert panel representing the Gastroenterological
More informationAcute Hepatitis in a Patient with NASH and Elevation of CMV-IgM
Acute Hepatitis in a Patient with NASH and Elevation of CMV-IgM Uta Drebber, MD Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationGI DISEASE WORKSHOP CASE STUDIES
GI DISEASE WORKSHOP CASE STUDIES American Academy of Insurance Medicine Triennial Course in Insurance Medicine 2012 Clifton Titcomb Jr., MD (Hannover Re) James Topic, MD (Protective Life) 1 CASE #1 Application
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationCaution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy Anjana A. Pillai, Emory University Frank A Anania, Emory University Brian L. Pearlman, Emory University
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationK For patients who have never been tested for HCV, it is. K It is suggested that HCV-infected patients not previously
http://www.kidney-international.org & 2008 DIGO Guideline 4: Management of HCV-infected patients before and after kidney transplantation idney International (2008) 73 (Suppl 109), S53 S68; doi:10.1038/ki.2008.87
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationChronic Hepatitis C. Risk Factors
Chronic Hepatitis C The hepatitis C virus is one of the most important causes of chronic liver disease in the United States. Almost 4 million Americans or 1.8 percent of the U.S. population have an antibody
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationHepatitis E Vaccine Clinical Experience. Mrigendra P. Shrestha
Hepatitis E Vaccine Clinical Experience Mrigendra P. Shrestha 1 Hepatitis E in Nepal 2 Hepatitis E in Nepal Most common type of acute viral hepatitis Occurs in annual rainy season outbreaks Responsible
More informationdeveloped countries European Centre for Environment &Human Health Peninsula College of Medicine & Dentistry
HEV infection in developed countries Harry Dalton European Centre for Environment &Human Health Peninsula College of Medicine & Dentistry Talk outline: HEV HEV in developed countries Acute Chronic Seroprevalence
More informationHepatitis B and Interferon Philippe Sogni Paris-Descartes University, INSERM U-1016 and Hepatology unit, Cochin hospital, Paris; France PHC 2015
Hepatitis B and Interferon Philippe Sogni Paris-Descartes University, INSERM U-1016 and Hepatology unit, Cochin hospital, Paris; France PHC 2015 1 Prof. Philippe SOGNI, M.D., Ph.D. Affiliations Institut
More informationHepatitis E FAQs for Health Professionals
Hepatitis E FAQs for Health Professionals Index of Questions ± Overview and Statistics What is Hepatitis E? How common is Hepatitis E in the United States? Where is Hepatitis E most common? Are there different
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationDelta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne
Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment
More informationThe ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013
The ABC s (and D & E s) of the Viral Hepatitides Part 2 Thomas Novicki PhD DABMM Clinical Microbiologist Division of Laboratory Medicine novicki.thomas@marshfieldclinic.org Objectives 2 1. Explain the
More informationSeroprevalence of Hepatitis E Virus Infection among Swine Farmers and the General Population in Rural Taiwan
Seroprevalence of Hepatitis E Virus Infection among Swine Farmers and the General Population in Rural Taiwan Jian-Te Lee 1, Pei-Lan Shao 2, Luan-Yin Chang 2, Ning-Shao Xia 3, Pei-Jer Chen 4, Chun-Yi Lu
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationViral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP
Viral Hepatitis Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP Viral hepatitis Viral hepatitis must be considered in any patient presenting with hepatitis on LFTs (high
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationA "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist
A "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist Information regarding pathogenesis and appropriate management of chronic hepatitis C continues to evolve.
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationChronic Hepatitis E Infection in a Pediatric Female Liver Transplant Recipient
JCM Accepts, published online ahead of print on 1 October 2014 J. Clin. Microbiol. doi:10.1128/jcm.02286-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 Chronic Hepatitis E
More informationSovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.24 Subject: Sovaldi PegIntron Ribavirin Page: 1 of 6 Last Review Date: November 30, 2018 Sovaldi PegIntron
More informationTransfusion transmission of hepatitis E virus: an emerging issue
Review Article Page 1 of 7 Transfusion transmission of hepatitis E virus: an emerging issue Kenrad E. Nelson Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore,
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationVIRAL AND AUTOIMMUNE HEPATITIS WHAT IS HEPATITIS?
VIRAL AND AUTOIMMUNE HEPATITIS Arthur M. Magun, M.D. Clinical Professor of Medicine WHAT IS HEPATITIS? Inflammation of the liver Almost always, inflammation implies elevation in liver enzymes AST and ALT
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationHepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection
The Journal of Journal Infectious of Diseases Infectious Diseases Advance Access published May 27, 2016 MAJOR ARTICLE Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic
More informationPatients must have met all of the following inclusion criteria to be eligible for participation in this study.
Supplementary Appendix S1: Detailed inclusion/exclusion criteria Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Inclusion Criteria 1) Willing
More informationIs it the time to start blood screening for Hepatitis-E?
Is it the time to start blood screening for Hepatitis-E? Dr. Somnath Mukherjee MD, MAMS Assistant Professor All India Institute of Medical Sciences Bhubaneswar During last 25 years the safety of blood
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationHepatitis E Jacques Izopet Federative Institute of Biology & INSERM U1043 Toulouse University - France
IPFA/PEI 19th International Workshop on Surveillance and Screening of Blood Borne Pathogens Budapest 23-24 May 2012 Hepatitis E Jacques Izopet Federative Institute of Biology & INSERM U1043 Toulouse University
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationQUANTITATIVE HEPATITIS C VIRUS (HCV) RNA
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA Policy Number: PDS - 028 Effective Date:
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationInvestigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation
Investigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation J. Peng, W.F. Luo, B. Zhou and W.Q. Wen Department of Infectious
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationPrevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States
Koning et al. BMC Infectious Diseases (2015) 15:371 DOI 10.1186/s12879-015-1103-9 RESEARCH ARTICLE Open Access Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation
More informationHepatitis A Hepatitis D Hepatitis E HSV CMV EBV
Ammar Hassan PGY-4 Hepatotropic Viruses Nominal Viruses Hepatitis A Hepatitis D Hepatitis E HSV CMV EBV HEPATITIS A *Non-enveloped, single-stranded RNA virus. *Only one known serotype. *The primary route
More information